The first human clinical trial of IL-15 showed that NK and CD8+ T cells were amplified in STIE (peripheral blood) of patients with advanced melanoma and patients with renal cell carcinoma (RCC), but with severe adverse reactions [222]. This evidence concerns the gene CD8A and renal cell carcinoma.